Paul Siebert, MD
Infectious Disease · Denver, CONPI 1619395191
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Gilead at 42.2% of the total. 2025 is the largest year on record at $305, 8.8 times the $35 reported in 2019.
Across 53 payments — averaging $24.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$539
- AbbVie$195
- Merck$158
- Viiv Healthcare Company$154
- Shionogi Inc$100
- Melinta Therapeutics, LLC$25
- plus $106 from 6 others
What the payments were for
- Food & beverage$1,25198%
- Education$262%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 19 | $539 |
| AbbVie(2 entities) | 8 | $195 |
| Merck | 8 | $158 |
| Viiv Healthcare Company | 7 | $154 |
| Shionogi Inc | 4 | $100 |
| Melinta Therapeutics, LLC | 1 | $25 |
| La Jolla Pharmaceutical Company | 1 | $24 |
| Octapharma USA, Inc. | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| Insmed, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
How this compares
$1,277 in reported general payments places this provider in the 80th percentile of 146 infectious disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 26 | $10,284 |
| CeftriaxoneCeftriaxone Sodium | 37 | $3,201 |
| Ampicillin Sodium | 17 | $3,150 |
| Cefazolin Sodium | 31 | $1,287 |
| Doxycycline Hyclate | 18 | $647 |
| Cephalexin | 15 | $296 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Denver
- David GriffithDenver$252K
- Kenneth GreenbergDenver$163K
- Shannon KasperbauerDenver$94K
- David WylesDenver$11K
- Gwen HuittDenver$11K
- Sarah RowanDenver$11K
- Timothy JenkinsDenver$10K
- Martin KrsakDenver$6K
- Michelle BarronDenver$5K
- Westyn Branch-EllimanDenver$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.